Verana Health, a digital health company that delivers quality drug lifecycle and medical practice insights from an exclusive real-world data network, recently secured a $150 million Series E led by Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Novo Growth, the growth-stage investment arm of Novo Holdings.  Existing Verana Health investors GV (formerly Google Ventures), Casdin Capital, and Brook Byers also joined the round, as well as notable new investors, including the Merck Global Health Innovation Fund, THVC, and Breyer Capital. We are driven to create quality real-world data in ophthalmology, neurology and urology to accelerate quality insights across the drug lifecycle and within medical practices. Additionally, we are driven to advance the quality of care and quality of life for patients. DRIVE defines our internal purpose and is the galvanizing force that helps ground us in a shared corporate culture. DRIVE is: Diversity, Responsibility, Integrity, Voi Apply now and work remotely at Verana Health